Ask AI

Novel ADC Therapies for Relapsed/Refractory Large B-Cell Lymphoma: Translating the Latest Advances Into Community Oncology Practice

Enhance your clinical decision-making when managing relapsed/refractory DLBCL with the use of ADCs therapies informed by the latest clinical data and guideline recommendations to optimize patient outcomes via downloadable resources, including a live webinar and “Success Strategies” slideset, certified on-demand webcast, and expert-authored commentaries.

Share

Program Content

Events

  • Live Event Novel ADC Therapies
    Novel ADC Therapies for Relapsed/Refractory Large B-Cell Lymphoma: Translating the Latest Advances Into Community Oncology Practice
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

R/R DLBCL
Relapsed/Refractory DLBCL: Patient-Provider Communication Checklist
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: October 07, 2025

ADC in R/R DLBCL: Safety
Novel ADC Therapies for R/R DLBCL: Optimizing Patient Safety With Timely AE Recognition and Management
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2025

ADC in R/R DLBCL
Available Antibody-Drug Conjugates for R/R DLBCL: A Summary Resource 
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: January 06, 2026

Activities

Relapsed/Refractory Diffuse Large B-Cell Lymphoma With ADCs
Managing Relapsed/Refractory Diffuse Large B-Cell Lymphoma With ADCs: Answers to Frequently Asked Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from ADC Therapeutics and Pfizer Inc.

ADC Therapeutics

Pfizer, Inc.